<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1649">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648906</url>
  </required_header>
  <id_info>
    <org_study_id>DWB_GTM001</org_study_id>
    <nct_id>NCT02648906</nct_id>
  </id_info>
  <brief_title>A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of Choline alfoscerate and&#xD;
      Donepezil for cognitive improvements of patients with cerebrovascular injury in Alzheimer&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of ADAS-cog score compared with Baseline</measure>
    <time_frame>48 weeks</time_frame>
    <description>Primary outcome will be evaluated with ADAS-cog questionnaire 48 weeks after taking investigational product.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Choline alfoscerate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Choline alfoscerate and Donepezil&#xD;
concomitant administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Donepezil only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline alfoscerate</intervention_name>
    <arm_group_label>Choline alfoscerate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 56~90 male and female&#xD;
&#xD;
          2. Mini-Mental State Evaluation (MMSE) between 24 and 12&#xD;
&#xD;
          3. Score â‰¥ 2 at the New Rating Scale for Age-related White Matter Changes (ARWMC), the&#xD;
             rating scale of cerebral ischemic injury evaluated with MRI&#xD;
&#xD;
          4. Score 0.5, 1, 2 at CDR&#xD;
&#xD;
          5. presence of at least two of the following vascular risk factors: hypertension,&#xD;
             diabetes, obesity, ischemic heart disease, dyslipidemia, hyperhomocysteinemia,&#xD;
             smoking, previous cerebrovascular events and familiar history of&#xD;
             cardio-cerebrovascular diseases.&#xD;
&#xD;
          6. donepezil 10mg from 3 months ago, dose not changed during clinical trials&#xD;
&#xD;
          7. A subject who provided written informed consent to participate in this study and&#xD;
             cooperative with regard to compliance with study related constraints&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects allergic to or sensitive to the Investigational Product or applicable&#xD;
             ingredients&#xD;
&#xD;
          2. subject who has taken below medication 1 month before screening 1) Cholinesterase&#xD;
             Inhibitors 2) NMDA receptor antagonists 3) blood circulation supplements 4)&#xD;
             Acetyl-L-Carnitines 5) Nicergoline 6) Subject who has taken another medication that&#xD;
             can affect the result of primary outcome&#xD;
&#xD;
          3. subject that can't be evaluated with ADAS-cog, MMSE, NPI, ADL, CDR, Attention&#xD;
             Questionnaire Scale etc.&#xD;
&#xD;
          4. Asthma, COPD&#xD;
&#xD;
          5. Decompensated heart disease&#xD;
&#xD;
          6. Chronic renal failure or chronic liver disease&#xD;
&#xD;
          7. Malignant tumor&#xD;
&#xD;
          8. Subject that cant' be followed up for 12 months after Investigational drug was taken.&#xD;
&#xD;
        9 Subjects who are pregnant, lactating or who plan to be pregnant during the clinical&#xD;
        period or females of child bearing years who do not use available contraceptive methods 10.&#xD;
        Subject who has taken other clinical or licensed medication from another clinical trial&#xD;
        within 30 days prior screening period 11.Other subjects who are deemed not to be&#xD;
        appropriate for this clinical study in the discretion of investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jina Song</last_name>
    <phone>82-2-550-8865</phone>
    <email>jnsong058@daewoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Sungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

